Zobrazeno 1 - 10
of 64
pro vyhledávání: '"L. Gaboriau"'
Publikováno v:
Annales Pharmaceutiques Françaises. 81:720-729
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::84cc0db2f7ad3e31a92c7cec1e4bd743
https://doi.org/10.1016/j.pharma.2022.12.005
https://doi.org/10.1016/j.pharma.2022.12.005
Autor:
G Strobbe, L Gaboriau, M Abele, A Villain, C Aelbrecht-Meurisse, A Carnot, MC Le Deley, C Léguillette, I Sakji, F Feutry, G Marliot
Publikováno v:
Section 5: Patient safety and quality assurance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a40591ba9b4d309422712832fac0026
https://doi.org/10.1136/ejhpharm-2023-eahp.241
https://doi.org/10.1136/ejhpharm-2023-eahp.241
Autor:
L Gaboriau, Nadine Petitpain, Louise Carton, Sophie Gautier, Marc Lambert, Emmanuel Delaporte, Hélène Théophile, Cécile Yelnik
Publikováno v:
Therapies. 76:449-454
Summary Objective This study aimed to describe reports of psychiatric adverse drug reaction (ADR) in the spectrum of bipolar (manic features) or psychotic disorders that occurred under tumor necrosis factor alpha (TNF-α) inhibitors therapy. Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f87de3df4c43429da7f790e5d2346097
https://doi.org/10.1016/j.therap.2020.09.003
https://doi.org/10.1016/j.therap.2020.09.003
Publikováno v:
Annales pharmaceutiques francaises.
Dronabinol is a drug composed of synthetic delta-9-tetrahydrocannabinol. In France, dronabinol requires a named Temporary Utilisation Authorisation (TUA), for the treatment of refractory neuropathic pain. Few data currently exist concerning its effic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::93f76ea7a2f68c88c4493ed87c83ad1d
https://pubmed.ncbi.nlm.nih.gov/36513153
https://pubmed.ncbi.nlm.nih.gov/36513153
Autor:
A Picca, C Birzu, G Berzero, P Sanchez-Pena, L Gaboriau, F Vidil, T Lenglet, C Tafani, D Ricard, D Psimaras, K Bihan
Publikováno v:
Neuro-Oncology. 24:ii69-ii70
Background BRAF (BRAFi) and MEK inhibitors (MEKi) demonstrated significant efficacy in the treatment of BRAF-activated tumours, firstly melanoma. Nevertheless, they are not devoid of adverse events. Sparse reports in the literature suggest the potent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af459118205dd319a2a25bd10c191628
https://doi.org/10.1093/neuonc/noac174.241
https://doi.org/10.1093/neuonc/noac174.241
Publikováno v:
Annales de Dermatologie et de Vénéréologie. 147:667-671
Summary Introduction Ixekizumab is a recently developed biopharmaceutical used since 2016 in the US and Europe for the treatment of plaque psoriasis. Few adverse effects have been reported in the literature and ixekizumab is not known to increase the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7206858eb1fc995021eaa9d1c7f3e454
https://doi.org/10.1016/j.annder.2020.04.020
https://doi.org/10.1016/j.annder.2020.04.020
Publikováno v:
Annales de Dermatologie et de Vénéréologie. 147:446-450
Resume Introduction La dermatose bulleuse hemorragique (DBH) induite par l’heparine est un effet indesirable rare et benin dont nous rapportons deux cas. Observations Cas 1 : un homme de 81 ans presentait des bulles hemorragiques des membres et du
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0638bbb0a4158c8dcdddd4d26632209
https://doi.org/10.1016/j.annder.2019.08.021
https://doi.org/10.1016/j.annder.2019.08.021
Autor:
Thao Pham, Pauline Baudart, L. Gaboriau, I. Henry Desailly, René-Marc Flipo, E. Acquacalda, Laurent Peyrin-Biroulet, Jean-Guillaume Letarouilly, Bruno Gombert, E. Karimova, N. Sultan-Bichat, P. Claudepierre, L. Plastaras, Emmanuelle Dernis, Denis Jullien, Benjamin Pariente, Delphine Staumont-Sallé, Tristan Pascart, C. Girard, E. Bauer, Philippe Gaudin, Daniel Wendling, Arnaud Constantin, Xavier Guennoc, Stéphane Varin, X. Truchet, Philippe Goupille, D.L. Le, Sébastien Barbarot, B. Banneville, A. Pierache, Renaud Felten, Sylvain Lanot
Publikováno v:
Revue du Rhumatisme. 87:A100-A102
Introduction La question de la survenue de maladies inflammatoires chroniques de l’intestin (MICI) de novo (MICI-DN) sous inhibiteurs de l’interleukine 17 (anti-IL 17) a ete soulevee a partir des donnees des essais pivots. Les objectifs principau
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::87d3705acdf9145917f3957c9ef4b06a
https://doi.org/10.1016/j.rhum.2020.10.173
https://doi.org/10.1016/j.rhum.2020.10.173
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.